Edition:
United States

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

16.59USD
18 May 2018
Change (% chg)

$-0.22 (-1.31%)
Prev Close
$16.81
Open
$16.95
Day's High
$17.05
Day's Low
$16.51
Volume
34,585
Avg. Vol
73,679
52-wk High
$26.74
52-wk Low
$11.81

Latest Key Developments (Source: Significant Developments)

Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
Friday, 12 Jan 2018 05:14pm EST 

Jan 12 (Reuters) - Kala Pharmaceuticals Inc ::ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10.  Full Article

Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121
Friday, 5 Jan 2018 07:00am EST 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE.KALA PHARMACEUTICALS INC - KPI-121 0.25% WAS WELL-TOLERATED WITH ELEVATIONS IN IOP SIMILAR TO PLACEBO.KALA PHARMACEUTICALS INC - IN STRIDE 1 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS- OCULAR DISCOMFORT SEVERITY AT DAY 15 IN ITT POPULATION SHOWED IMPROVEMENT BUT DID NOT REACH STATISTICAL SIGNIFICANCE IN STRIDE 2.KALA PHARMACEUTICALS INC - IN STRIDE 2 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS INC - WILL CONTINUE TO ANALYZE RESULTS OF BOTH PHASE 3 TRIALS.  Full Article

Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA
Friday, 5 Jan 2018 06:50am EST 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION.KALA PHARMACEUTICALS INC - BRAND NAME FOR KPI-121 1%, INVELTYS, HAS BEEN CONDITIONALLY APPROVED BY FDA.KALA PHARMA-FDA INDICATES APPLICATION FOR INVELTYSTM SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW,SET PDUFA TARGET ACTION DATE OF AUGUST 24,2018​.  Full Article

Kala Pharmaceuticals reports Q3 loss per share $0.56
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Kala Pharmaceuticals Inc :Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.56.Kala Pharmaceuticals - ‍Top-line results from phase 3 clinical program for KPI-121 0.25% in patients with dry eye disease are expected by end of 2017​.Kala Pharmaceuticals Inc - ‍Expects that its existing cash on hand will enable it to fund operations through Q2 of 2019​.  Full Article

Kala Pharmaceuticals submits new drug application for Inveltystm
Wednesday, 25 Oct 2017 08:00am EDT 

Oct 25 (Reuters) - Kala Pharmaceuticals Inc :Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct).  Full Article

Wellington Management Group reports 11.84 pct passive stake in Kala Pharmaceuticals - SEC filing‍​
Thursday, 10 Aug 2017 11:21am EDT 

Aug 10 (Reuters) - Wellington Management Group LLP::Wellington Management Group LLP reports 11.84 percent passive stake in Kala Pharmaceuticals Inc as of July 31, 2017 - SEC filing‍​.  Full Article

Kala Pharmaceuticals shares open at $16.70 in debut vs IPO price of $15/shr
Thursday, 20 Jul 2017 09:58am EDT 

July 20 (Reuters) - :Kala Pharmaceuticals Inc shares open at $16.70 in debut on the Nasdaq versus IPO price of $15.00 per share.  Full Article

Kala Pharma announces pricing of initial public offering
Thursday, 20 Jul 2017 08:00am EDT 

July 20 (Reuters) - Kala Pharmaceuticals Inc ::Kala Pharmaceuticals announces pricing of initial public offering.Says initial public offering of 6.00 million common shares priced at $15.00per share.Kala Pharmaceuticals Inc - priced its initial public offering for aggregate gross proceeds of approximately $90.0 million.  Full Article

Kala Pharma sees IPO of 6 mln shares priced between $14-$16/shr
Monday, 10 Jul 2017 07:02am EDT 

July 10 (Reuters) - Kala Pharmaceuticals Inc ::Kala Pharmaceuticals sees IPO of 6 million shares of co's common stock priced between $14.00 and $16.00 per share.  Full Article